Literature DB >> 2653057

Double-blind controlled trial comparing carbamazepine to oxazepam treatment of alcohol withdrawal.

R Malcolm1, J C Ballenger, E T Sturgis, R Anton.   

Abstract

Of 86 alcoholic men with severe alcohol withdrawal who began a double-blind controlled study comparing carbamazepine, 800 mg/day, to oxazepam, 120 mg/day, 66 (carbamazepine, N = 32; oxazepam, N = 34) completed the 7-day trial. In general, the drugs were found to be equally efficacious in treating the withdrawal syndrome and not significantly different with respect to side effects. The subjects taking oxazepam had an increase in global psychological distress from day 3 to day 7, and those taking carbamazepine exhibited a decline. The study suggests that carbamazepine is as effective and safe as benzodiazepine treatment for alcohol withdrawal.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2653057     DOI: 10.1176/ajp.146.5.617

Source DB:  PubMed          Journal:  Am J Psychiatry        ISSN: 0002-953X            Impact factor:   18.112


  18 in total

1.  Treatment of alcohol withdrawal syndrome with a combination of tiapride/carbamazepine: results of a pooled analysis in 540 patients.

Authors:  Michael Soyka; Peggy Schmidt; Michael Franz; Thomas Barth; Michael de Groot; Thorsten Kienast; Thomas Reinert; Christoph Richter; Greif Sander
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2006-08-17       Impact factor: 5.270

Review 2.  Clinical issues related to the costs of alcoholism.

Authors:  M O Howard; R W McGuffin; A J Saxon; K L Sloan; R D Walker
Journal:  Pharmacoeconomics       Date:  1996-02       Impact factor: 4.981

Review 3.  Anticonvulsants for the treatment of alcohol withdrawal syndrome and alcohol use disorders.

Authors:  Christopher J Hammond; Mark J Niciu; Shannon Drew; Albert J Arias
Journal:  CNS Drugs       Date:  2015-04       Impact factor: 5.749

Review 4.  Who needs inpatient detox? Development and implementation of a hospitalist protocol for the evaluation of patients for alcohol detoxification.

Authors:  John R Stephens; E Allen Liles; Ria Dancel; Michael Gilchrist; Jonathan Kirsch; Darren A DeWalt
Journal:  J Gen Intern Med       Date:  2014-01-07       Impact factor: 5.128

Review 5.  Relapse Prevention in Alcoholism : Recent Advances and Future Possibilities.

Authors:  M Soyka
Journal:  CNS Drugs       Date:  1997-04       Impact factor: 5.749

Review 6.  Recent advances in the pharmacotherapy of alcoholism.

Authors:  Hugh Myrick; Raymond Anton
Journal:  Curr Psychiatry Rep       Date:  2004-10       Impact factor: 5.285

Review 7.  Recommended drug treatment strategies for the alcoholic patient.

Authors:  A Schaffer; C A Naranjo
Journal:  Drugs       Date:  1998-10       Impact factor: 9.546

8.  Alcohol withdrawal: a nationwide survey of inpatient treatment practices.

Authors:  R Saitz; L S Friedman; M F Mayo-Smith
Journal:  J Gen Intern Med       Date:  1995-09       Impact factor: 5.128

9.  Coadministration of disulfiram and lorazepam in the treatment of alcohol dependence and co-occurring anxiety disorder: an open-label pilot study.

Authors:  Michael P Bogenschutz; Snehal Bhatt; Juliane Bohan; Bellelizabeth Foster; Paul Romo; Claire E Wilcox; J Scott Tonigan
Journal:  Am J Drug Alcohol Abuse       Date:  2016-05-16       Impact factor: 3.829

Review 10.  Drug-induced seizures in the elderly. Causative agents and optimal management.

Authors:  K L Franson; D P Hay; V Neppe; W Y Dahdal; W U Mirza; G T Grossberg; D M Chatel; P A Szwabo; S Kotegal
Journal:  Drugs Aging       Date:  1995-07       Impact factor: 3.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.